510(k) · Cleared
ClearedBD Phoenix Automated Microbiology System - Moxifloxacin-0.125-8 and Ciprofloxacin-0.25 - 4 UG/ML
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Becton, Dickinson & CO · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Cleared on Apr 12, 2006 as substantially equivalent to K020321 (Becton, Dickinson & CO, 2002) and 2 other predicates after a 75-day review. Its family tree reaches back 2 generations to 2002. 1 later device descends from it.
- Decided
- Apr 12, 2006
- Review
- 75 days
- Class
- Class II
- Product code
- LON
- Recalls
- None
- Predicates
- 4
Its longest line of descent runs back 2 generations to K020322 (2002). 5 ancestors in all. 1 later device descends from it, 1 citing it directly.
- Root · 2 generations backK020322 BD Phoenix Automated Microbiology SystemBecton, Dickinson & CO · 2002
- 1 generation backK031306 BD Phoenix Automated Microbiology System - Moxifloxacin Gram PositiveBecton, Dickinson & CO · 2003
- This deviceK060217 BD Phoenix Automated Microbiology System - Moxifloxacin-0.125-8 and…Becton, Dickinson & CO · 2006
- Descendant · cites it directly · 0 of its ownK233986 BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin…Becton, Dickinson and Company · 2024
Most influential descendants
Showing 1 of 1 · See all- K233986BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)Becton, Dickinson and Company · 2024 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K020322 | BD Phoenix Automated Microbiology System | Becton, Dickinson & CO | 2002 | — |
| −1 | K031306 | BD Phoenix Automated Microbiology System - Moxifloxacin Gram Positive | Becton, Dickinson & CO | 2003 | — |
| 0 (this device) | K060217 | BD Phoenix Automated Microbiology System - Moxifloxacin-0.125-8 and… | Becton, Dickinson & CO | 2006 | — |
| +1 | K233986 | BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) | Becton, Dickinson and Company | 2024 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2002 | 2 | 0 |
| 2005 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2024 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LON device
- #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (4)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary; numbers the summary cites that cannot be its predicate are marked – and kept off the family tree.
| Type | Number | Device | Decided |
|---|---|---|---|
| Kept off the family tree | P050510 | VITEK® System Not in FDA’s 510(k), De Novo or PMA lists as we hold them (a misreading, a typo, or a number FDA does not list), so it is kept off the family tree | |
| * | K020321 | BD Phoenix Automated Microbiology SystemSummary page 1…No. N505 10) and BD PhoenixTM Automated Microbiology System with Gatifloxacin (K020321, May 23,2002, Moxifloxacin (K031306 June 2, 2003) and Ciprofloxacin (K052269,… | 2002 |
| * | K031306 | BD Phoenix Automated Microbiology System - Moxifloxacin Gram PositiveSummary page 1…Automated Microbiology System with Gatifloxacin (K020321, May 23,2002, Moxifloxacin (K031306 June 2, 2003) and Ciprofloxacin (K052269,… | 2003 |
| * | K052269 | BD Phoenix Automated Microbiology System -Ciprofloxacin GNSummary page 1…n (K020321, May 23,2002, Moxifloxacin (K031306 June 2, 2003) and Ciprofloxacin (K052269, October 3, 2005). INTENDED USE: The BD Phoenix TM A… | 2005 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K233986 | BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) | 2024 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 4 years and passes through 1 company; a new generation was cleared every 2.9 years on median.
- 1 of the 5 ancestors has a recall of any class.
- Of its descendants, K233986 (Becton, Dickinson and Company, 2024) has gone furthest, with 0 descendants of its own.
- 102 other devices also cite its predicate K020321.
How does its category compare?
All LON devicesLON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LON
5in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LON
90in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LON
1in 2025
Class I (2 since 2007) Class II/III not classified
Adverse event reports per year · LON
690in 2025
MAUDE reports naming product code LON, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 19 | 50 | 0 | 3 |
| 2008 | 7 | 66 | 1 | 1 |
| 2009 | 8 | 76 | 0 | 0 |
| 2010 | 1 | — | 116 | 3 |
| 2011 | 8 | 85 | 3 | 4 |
| 2012 | 10 | 200 | 3 | 9 |
| 2013 | 7 | 115 | 0 | 3 |
| 2014 | 4 | 90 | 2 (2) | 10 |
| 2015 | 0 | — | 0 | 41 |
| 2016 | 3 | 242 | 2 | 94 |
| 2017 | 10 | 89 | 1 | 197 |
| 2018 | 4 | 88 | 6 | 512 |
| 2019 | 8 | 84 | 1 | 315 |
| 2020 | 5 | 81 | 8 | 218 |
| 2021 | 5 | 268 | 0 | 232 |
| 2022 | 8 | 189 | 15 | 180 |
| 2023 | 11 | 210 | 0 | 453 |
| 2024 | 2 | — | 1 | 418 |
| 2025 | 5 | 90 | 1 | 690 |
| 2026 | 4 | 146 | 6 | — |
What is it indicated for?
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus. This…
Read the full statement (226 words)
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus.
This premarket notification is for the BD PhoenixTM Automated Microbiology System with Moxifloxacin (0.125-8 Itg/mL) and additional Gram-positive organism groups and Ciprofloxacin (0.25-4 gg/mL) and additional Gram-negative organism groups.
Moxifloxacin has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Enterococcus faecalis (many strains are only moderately susceptible)
Staphylococcus aureus (methicillin-susceptible strains only)
Active In Vitro Against:
Staphylococcus epidermidis (methicillin-susceptible strains only)
Cirpofloxacin has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Citrobacter koseri
Citrobacter freundii
Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Morganella morganii
Proteus mirabillis
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Salmonella typhi
Serratia marscescens
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Active In Vitro Against:
Acinetobacter Iwoffi
Aeromonas hydrophila
Edwardsiella tarda
Enterobacter aerogenes
Klebsiella oxytoca
Salmonella enteritidis
Yersinia enterocolitica
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K060217 · printed Nov 6, 2026
Cite this page
510(k) Report. “K060217: BD Phoenix Automated Microbiology System - Moxifloxacin-0.125-8 and Ciprofloxacin-0.25 - 4 UG/ML.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K060217
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026